Meningococcal disease treatment Market: Global Industry Analysis 2012-2016 and Opportunity Assessment 2017-2027


Future Market Insights

$ 5000

Meningococcal disease is an extreme contamination of meninges, the slim layers of tissue covering mind and spinal rope, brought about by the microscopic organisms Neisseria meningitidis. This microscopic organisms can cause bloodstream disorder (septicemia). Bacterial meningitis is extreme as a result of fast growth and a huge fatality risk related with the infection.

Rising Importance of Vaccination to Augment Demand in Market

  • The key factor behind the development of worldwide meningococcal disease treatment market is rising frequencies of meningococcal diseases in creating countries particularly African and Asian nations. Administrative associations and NGOs too have contributed as far as finances are concerned, trading antibodies and medications and leading mass immunization programs also towards diseases counteractive action in African and Asian nations.
  • According to the geography, the meningococcal disease treatment market is classified into Asia-Pacific, Europe, North America, and Rest of the World (RoW), where the North American locale controls the market by keeping significant offers in 2013. Indeed, Asia-Pacific is required to develop at a decent pace in coming years. The huge improvement in the region is upheld by government awareness projects and vaccination drives. Besides, there have been activities from different healthcare organizations to spread significance of immunization for adults and babies have filled the market demand for meningococcal antibodies in various nations.
  • Different figures, for example, rise mindfulness about the antibody for meningococcal disease and its inoculation has supported the local development in the market. With the development in innovative work, ascend in cognizance of event of disease and extending government reinforce in routine inoculation of the meningococcal disease treatment market is grabbing the pace as a treatment of decision in patients. This market is foreseen to grow at a sound CAGR in the future.

Meningococcal disease is a severe infection of meninges, the thin layers of tissue covering brain and spinal cord, caused by the bacteria Neisseria meningitidis. This bacteria can also cause bloodstream infections (septicemia). Bacterial meningitis is severe because of rapid onset and a significant risk of death associated with infection. Infection of Neisseria meningitidis may also result in mental retardation, deafness and epilepsy. 12 strains of N. meningitidis have been identified, 6 of which (A, B, C, W, X and Y) are capable enough to cause epidemics. Meningococcal septicaemia is a rare but fatal form of meningococcal disease characterized by a haemorrhagic rash and rapid circulatory collapse. Rigid neck, high fever, sensitivity to light, dilemma, headaches and vomiting are most common symptoms of meningococcal disease. The highest rate of disease is found across 26 countries of sub-Saharan Africa known as the extended meningitis belt. The disease can be treated by a number of antibiotics and vaccines are also available for the prevention of disease.According to the Centers for Disease Control and Prevention (CDC), teenagers and young adults are most vulnerable to get meningitis.

Meningococcal disease treatment Market: Drivers and Restraints

The key contributor to the growth of global Meningococcal disease treatment market is rising incidences of meningococcal diseases in developing nations especially African and Asian countries. Governmental organisations and NGOs as well have contributed in terms of financial grants, exporting vaccines and medicines and conducting mass vaccination programmes as well towards diseases prevention in African and Asian countries. Developed countries are also contributing significantly in terms of innovative products. North America and European nations are leading as far as the research and development is concerned. Poverty, illiteracy, lack of awareness and insufficient efforts by governments to reform healthcare services in developing countries are impeding the market growth.

Meningococcal disease treatment Market: Segmentation

Global Meningococcal disease treatment Market has been segmented on the basis of types of therapies, Route of Administration, distribution channels and region.

Based on types of therapies, the global Meningococcal disease treatment Market is segmented into:

  • Antibiotics

    • Penicillin

    • Ampicillin

    • Chloramphenicol

    • Ceftriaxone

  • Vaccines

    • Bivalent (groups A and C)

    • Trivalent (groups A, C and W)

    • Tetravalent (groups A, C, Y and W)

Based on the route of Administration, the global Meningococcal disease treatment Market is segmented into:

  • Injectable

  • Oral

Based on the distribution channels, the global Meningococcal disease treatment Market is segmented into:

  • Retail Pharmacies

  • Hospital Pharmacies

  • Clinics

  • Mass Vaccination Programmes

Meningococcal disease treatment Market: Overview

Global Meningococcal disease treatment market is highly fragmented with the presence of multiple players. Vaccines for the prevention of the disease are developed and manufactured by a few multi-national players such as Pfizer Inc., GlaxoSmithKline plc, Sanofi Pasteur Inc. and Novartis AG while antibiotics for the treatment of disease are manufactured by both domestic and international players. Generic versions are easily available worldwide. Meningococcal disease is endemic in China and India and have been under-recognized. According to the Global Meningococcal Initiative (GMI), serogroup A disease is most dominant in low-income countries such as India and the Philippines, while serogroups C is the major causative agent inTaiwan, Japan, and Korea. China has observed a mixed epidemiology of A, B, C, and W serogroups. The incidence of meningococcal disease in Latin American countries differs from less than 0.1 cases per 100,000 in Mexico to two cases per 100,000 in Brazil.

Meningococcal disease treatment Market: Region-wise Outlook

Geographically, Meningococcal disease treatment  Market  is segmented into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, Japan, Middle East and Africa. Asian and African countries are the largest meningococcal disease treatment Market because of prevalence of a huge population in need for treatment and prevention of the disease. According to the World Health Organization (WHO), the region of sub-Saharan Africa ranging from Senegal in the west to Ethiopia in the east involving 26 countries, known as the extended meningitis belt, has the highest rates of the disease. The market in North America and the European countries is stable because of limited numbers of infections owing to better healthcare services, better environment and continuous efforts of governments to eradicate such devastating diseases. According to the Centers for Disease Control and Prevention (CDC), rates of meningococcal disease have been declining in the United States since the late 1990s and have reduced to just 375 total cases of meningococcal disease in 2015 representing incidence rate of 0.18 cases per 100,000 persons.

Meningococcal disease treatment Market: Key Players

The key players in the global Meningococcal disease treatment Market include Pfizer Inc., GlaxoSmithKline plc, Sanofi Pasteur Inc., Novartis AG, WOCKHARDT, Sandoz International GmbH, Kent Pharmaceuticals, F. Hoffmann-La Roche Ltd, Stravencon Limited and Athlone Laboratories.

MRR.BIZ has been compiled in-depth market research data in the report after exhaustive primary and secondary research. Our team of able, experienced in-house analysts has collated the information through personal interviews and study of industry databases, journals, and reputable paid sources.

The report provides the following information:

  • Tailwinds and headwinds molding the market’s trajectory
  • Market segments based on products, technology, and applications
  • Prospects of each segment
  • Overall current and possible future size of the market
  • Growth pace of the market
  • Competitive landscape and key players’ strategies

The main aim of the report is to:

  • Enable key stakeholder’s in the market bet right on it
  • Understand the opportunities and pitfalls awaiting them
  • Assess the overall growth scope in the near term
  • Strategize effectively with respect to production and distribution

MRR.BIZ is a leading provider of strategic market research. Our vast repository consists research reports, data books, company profiles, and regional market data sheets. We regularly update the data and analysis of a wide-ranging products and services around the world. As readers, you will have access to the latest information on almost 300 industries and their sub-segments. Both large Fortune 500 companies and SMEs have found those useful. This is because we customize our offerings keeping in mind the specific requirements of our clients.